학술논문
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Document Type
Article
Author
Source
In: Multiple Sclerosis Journal . (Multiple Sclerosis Journal, October 2022, 28(12):1944-1962)
Subject
Language
English
ISSN
14770970
13524585
13524585